MedTrace Logo

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

NCT07281677 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-12-15

No results posted yet for this study

Summary

This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years

Conditions

Interventions

BIOLOGICAL

bivalent HPV vaccine

Bivalent HPV vaccine produced by Shanghai Zerun Biotechnology Co.,Ltd. or Wantai BioPharm.

BIOLOGICAL

9-valent HPV vaccine

9-valent HPV vaccine is produced by Wantai BioPharm or Merck Sharp \& Dohme LLC.

Sponsors & Collaborators

  • Zhejiang Provincial Center for Disease Control and Prevention

    lead OTHER_GOV

Principal Investigators

  • Shenyu Wang · Zhejiang Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
9 Years
Max Age
14 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-20
Primary Completion
2028-12-20
Completion
2029-11-13

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07281677 on ClinicalTrials.gov